BTIG Research Downgrades Kura Oncology (NASDAQ:KURA) to Neutral

Kura Oncology (NASDAQ:KURA - Get Free Report) was downgraded by investment analysts at BTIG Research from a "buy" rating to a "neutral" rating in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports.

Several other research firms also recently issued reports on KURA. TD Cowen reissued a "buy" rating on shares of Kura Oncology in a research report on Thursday, November 21st. JMP Securities reaffirmed a "market outperform" rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Tuesday, November 19th. Stifel Nicolaus downgraded shares of Kura Oncology from a "buy" rating to a "hold" rating and decreased their target price for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Wedbush reaffirmed an "outperform" rating and issued a $37.00 price target on shares of Kura Oncology in a research report on Monday, November 4th. Finally, HC Wainwright boosted their price objective on Kura Oncology from $37.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $27.13.

Kura Oncology Stock Up 1.6 %

NASDAQ:KURA traded up $0.14 during trading hours on Thursday, reaching $8.79. The company had a trading volume of 752,907 shares, compared to its average volume of 1,884,173. The business's 50-day simple moving average is $8.74 and its two-hundred day simple moving average is $14.95. Kura Oncology has a twelve month low of $6.98 and a twelve month high of $24.17. The firm has a market cap of $683.59 million, a price-to-earnings ratio of -3.73 and a beta of 0.78. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($0.64) by $0.01. During the same period last year, the company earned ($0.50) EPS. On average, equities analysts expect that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Mollie Leoni sold 4,963 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,255 shares of company stock worth $100,739. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently made changes to their positions in KURA. nVerses Capital LLC bought a new position in shares of Kura Oncology during the third quarter valued at about $25,000. E Fund Management Co. Ltd. bought a new stake in shares of Kura Oncology in the 4th quarter worth approximately $90,000. Corient Private Wealth LLC bought a new stake in Kura Oncology in the fourth quarter worth $109,000. China Universal Asset Management Co. Ltd. raised its position in shares of Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock worth $144,000 after purchasing an additional 1,750 shares during the last quarter. Finally, Point72 DIFC Ltd bought a new position in Kura Oncology in the 3rd quarter worth about $146,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.